Loss of ability to work and ability to live independently in Parkinson's disease. by Jasinska-Myga, B. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Loss of ability to work and ability to live independently in 
Parkinson's disease. 
Authors: Jasinska-Myga B, Heckman MG, Wider C, Putzke JD, Wszolek 
ZK, Uitti RJ 
Journal: Parkinsonism &amp; related disorders 
Year: 2012 Feb 
Volume: 18 
Issue: 2 
Pages: 130-5 
DOI: 10.1016/j.parkreldis.2011.08.022 
 
Loss of ability to work and ability to live independently in
Parkinson’s Disease
Barbara Jasinska-Myga, MD, PhD1,2, Michael G. Heckman, MS3, Christian Wider, MD1,4,
John D. Putzke, PhD1, Zbigniew K. Wszolek, MD1, and Ryan J. Uitti, MD1,*
1Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA 2Department of Neurology,
Medical University of Silesia, Katowice, Poland 3Biostatistics Unit, Mayo Clinic, Jacksonville, FL,
USA 4Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland
Abstract
Objective—Ability to work and independent living capacity are of particular concern for patients
with Parkinson’s disease (PD). We utilized a series of PD patients able to work or live
independently at baseline, and evaluated potential risk factors for the two separate outcomes of
loss of ability to work and loss of ability to live independently.
Methods—The series was comprised of 495 PD patients followed prospectively. Ability to work
and ability to live independently were based on clinical interview and examination. Cox regression
models adjusted for age and disease duration were used to evaluate associations of baseline
characteristics with loss of ability to work and loss of ability to live independently.
Results—Higher UPDRS dyskinesia score, UPDRS instability score, UPDRS total score, Hoehn
and Yahr stage, and presence of intellectual impairment at baseline were all associated with
increased risk of future loss of ability to work and loss of ability to live independently (P≤0.0033).
Five years after initial visit, for patients ≤70 years of age with a disease duration ≤4 years at initial
visit, 88% were still able to work and 90% to live independently. These estimates worsened as age
and disease duration at initial visit increased; for patients >70 years of age with a disease duration
>4 years, estimates at 5 years were 43% and 57%, respectively.
Conclusions—The information provided in this study can offer useful information for PD
patients in preparing for future loss of ability to perform activities of daily living.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive disorder associated with functional
decline. Ability to work and independent living capacity are two important activities of daily
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living (ADL) of particular concern for patients with PD wondering how long their capability
may last. Inability to continue working causes financial concerns and place a major
individual and societal burden. Moreover, motor disabilities and increasing dependence on
others in daily life has an important influence on patients’ and caregivers’ quality of life.
Previous research has shown that the rate of premature unemployment due to PD ranges
from 27% to 70%. Older age, later disease onset, longer disease duration, greater severity of
symptoms and lack of support from coworkers are the main factors responsible for giving up
work [1-6]. Moreover, a recent report and systematic review presented axial impairment and
difficulties with ambulation as important predictors of disability in patients with PD [7-9].
Although these are important findings, methodological limitations of previous studies
(retrospective or cross-sectional nature, limited range of predictive factors, narrowed age at
onset and severity of disease, univariate analysis, lack of adjustment for multiple testing)
influence the understanding of predictive factors associated with the ability to work and live
independently. Moreover, since ability to work and independent living are influenced by an
individual’s cultural background, it is more important to assess whether the individual could
perform a task if needed (present study) than to determine whether the individual is
currently involved in doing it (most previous studies).
The current study uses a prospective, clinical cohort of patients with PD able to work or live
independently at baseline visit, with a broad range of demographic, historical and clinical
characteristics. In order to provide clinicians, patients, and families with information
regarding the likely length of time patients will be able to function in everyday life, we
examined associations of patient characteristics and disease information with the two
separate outcomes of loss of ability to work and loss of ability to live independently, and
estimated the future likelihood of these two outcomes after baseline visit.
Design and Methods
Patients and procedures
The original cohort consisted of 825 consecutive patients diagnosed with PD by one
movement disorders neurologist (RJU) at the Mayo Clinic, Jacksonville, Florida, from 1994
to 2002, who were still able to work or live independently at baseline visit. Patients were
excluded if they had no follow-up visit, had follow-up visits occurring less than 90 days
after the baseline visit, or if information was not collected regarding age or disease duration
at baseline visit. Of the 825 patients, 495 met inclusion criteria. After baseline visit, patients
were generally seen on a yearly basis. Follow-up visits included in the present study extend
to the year 2008. Of the 495 patients, 303 were able to work at baseline and as such were
included in analysis involving loss of ability to work, while 491 were able to live
independently at baseline and were included in analysis involving loss of ability to live
independently.
In order to assess potential bias, we compared characteristics of the 330 patients who were
excluded. These patients differed significantly (P≤0.05) from the 495 patients included in
the study in regard to disease duration (Median: 58 vs. 45 months), personal history of
depression (22% vs. 31%), current depression (19% vs. 12%), Hoehn and Yahr stage >2
(39% vs. 27%), any impairment on ADL score (39% vs. 17%), Unified Parkinson’s Disease
Rating Scale (UPDRS) instability score (Median: 3 vs. 2), and UPDRS dyskinesia score >0
(24% vs. 16%). There were no other significant differences in demographic or disease
information between the two groups.
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The diagnosis of PD was made by virtue of patients having at least two of the following
features: bradykinesia, resting tremor, rigidity, and postural instability, without any other
explanation for parkinsonism or atypical features [10, 11].
Demographic, historical, and clinical information was collected as previously described in
detail [12, 13]. We used the modified Hoehn and Yahr scale and the modified UPDRS motor
score with additional items for arm swing and dyskinesia, as reported previously [13]. All
data were entered prospectively into an electronic database in accordance with the Mayo
Clinic IRB-approved protocol. Written informed consent was obtained from all patients
participating in the study at baseline visit.
Two separate primary endpoints were captured as part of a routine semi-structured,
physician-based (RJU) interview. One endpoint, loss of ability to work, was defined as
inability to work in a job with light physical/social requirements (e.g. work in a retail
department store). An important point to highlight is that because loss of ability to work can
be considered as a measure of ability to function socially in everyday life, it was appropriate
to consider patients of all ages in this assessment, not just in those younger than usual
retirement age. The second endpoint, loss of ability to live independently was measured
uniformly by observation and asking patients, spouses and caregivers about abilities to
dress, eat, use toilet, take care of own hygiene, walk, travel and perform household activities
independently.
Statistical analysis
The Kaplan-Meier method was used to estimate the proportion of patients still able to work,
and the proportion of patients still able to live independently after baseline visit, censoring at
the date of last follow-up. Due to the fact that both age and disease duration are known to be
highly related to each of the two endpoints, we stratified our sample into four groups based
on the combination of approximate median age at baseline (≤70 years, >70 years) and
approximate median symptomatic disease duration (≤4 years, >4 years), and calculated
Kaplan-Meier estimates for each of these four patient groups. Relative risks (RRs) and 95%
confidence intervals (CIs) resulting from Cox proportional hazards regression models
adjusted for age and disease duration were used to evaluate associations of baseline patient
characteristics with the two separate endpoints of loss of ability to work and loss of ability to
live independently. For easier interpretation of results, Hoehn and Yahr stage was
dichotomized as ≤2 vs. >2, and UPDRS dyskinesia score was dichotomized as 0 vs. >0 in all
analyses.
In evaluation of associations of patient baseline characteristics with the endpoints of loss of
ability to work and loss of ability to live independently, we adjusted for multiple testing
using the Bonferroni method. With 15 different statistical tests performed in association
analysis for each endpoint, p-values ≤ 0.0033 were considered statistically significant.
Because we did not aim to evaluate whether age and disease duration are associated with
loss of ability to work and loss of ability to live independently as these associations are
already known, we did not include these two association tests in our Bonferroni adjustment
for multiple testing. All statistical analyses were performed using S-Plus (version 8.0.1;
Insightful Corporation, Seattle, Washington).
Results
Patient demographic and disease information
In the overall cohort of 495 patients, individuals were predominantly males (68%), with a
median age of 66 years at PD symptomatic onset and of 71 years at the time of their first
(baseline) visit. Median length of follow-up from baseline visit was 4.0 years (min=92 days,
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max=12.7 years). These and other demographic and clinical characteristics are provided in
Table 1.
Loss of ability to work and to live independently
Kaplan-Meier estimated proportions of patients still able to work and still able to live
independently after baseline visit are shown in Table 2, and Figures 1 and 2. These Kaplan-
Meier estimates are provided separately according to median age at baseline (≤70 years, >70
years) and median symptomatic disease duration (≤4 years, >4 years). At 5 years following
baseline visit, the proportions of patients still able to work were as follows: 88% (age≤70,
disease duration ≤4), 66% (age≤70, disease duration >4), 58% (age>70, disease duration≤4),
and 43% (age>70, disease duration>4). At 5 years following baseline visit, the proportion of
patients still able to live independently were 90% (age ≤70, disease duration ≤4), 68% (age
≤70, disease duration >4), 80% (age >70, disease duration ≤4), and 57% (age >70, disease
duration >4).
Predictors of loss of ability to work and loss of ability to live independently
Associations of baseline demographic and disease information with the separate endpoints
of loss of ability to work and loss of ability to live independently are displayed in Table 3.
A significantly increased risk of future loss of ability to work was observed for patients with
intellectual impairment (RR: 3.58, P=0.0033), Hoehn and Yahr stage > 2 (RR: 2.05,
P=0.0009), higher UPDRS instability score (RR: 2.04 [3 point increase], P=6×10-7), and
higher UPDRS total score (RR: 1.60 [20 point increase], P=0.0017). No significant
association with loss of ability to work was observed for the other items evaluated after
adjustment for multiple testing.
We identified a significantly increased risk of future loss of ability to live independently in
patients with intellectual impairment (RR: 3.55, P=1×10-5), Hoehn and Yahr stage >2 (RR:
1.99, P=7×10-5), higher UPDRS bradykinesia score (RR: 1.38 [10 point increase],
P=0.0019), higher UPDRS instability score (RR: 1.73 [3 point increase], P=2×10-8), higher
UPDRS dyskinesia score >0 (RR: 2.39, P=2×10-5), higher UPDRS total score (RR: 1.44 [20
point increase], P=0.0019), and any impairment on ADL score (RR: 2.13, P=8×10-5). No
significant association with loss of ability to work was noted for the remaining items
evaluated after adjustment for multiple testing. Of note, as expected, increased age was
strongly associated with risk of loss of ability to work (RR: 2.62, P=4×10-9) and loss of
ability to live independently (RR: 2.32, P=2×10-7), as well increased disease duration was
strongly associated with risk of loss of ability to work (RR: 1.81, P=0.0002) and loss of
ability to live independently (RR: 2.49, P=2×10-8).
Discussion
The present study examines the associations of patient characteristics and disease
information with future loss of ability to work and loss of ability to live independently, in
individuals diagnosed with PD and able to work or live independently at baseline. In
addition to older age at baseline and longer disease duration [1, 5, 7], our study has
identified a number of predictors associated with an increased risk for loss of ability to work
and to live independently, providing patients and caregivers with valuable information.
Our results indicate that more advanced disease with intellectual impairment, higher Hoehn
and Yahr stage, increased UPDRS instability score, and increased UPDRS total score are
related to an increased risk of future loss of ability to work. Most strikingly, patients with
intellectual impairment at baseline were at an approximate 3.5-fold risk of future loss of
ability to work compared to others, while UPDRS instability score was strongly associated
Jasinska-Myga et al. Page 4
Parkinsonism Relat Disord. Author manuscript; available in PMC 2014 April 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
with increased risk of future loss of ability to work, with a 2-fold increased risk for each 3
point increase. Severity of PD symptoms was also presented by others as an important factor
involved in early cessation of work in individuals with PD [1, 6], together with lack of
support in the workplace, and available “opportunities” for early retirement [6].
Loss of ability to live independently after baseline visit was significantly associated with all
UPDRS scores except tremor, rigidity, and dominance score, and was also significantly
associated with intellectual impairment, higher Hoehn and Yahr stage, and any impairment
on ADL score. Consistent with findings regarding loss of ability to work, loss of ability to
live independently was also most pronounced in patients with intellectual impairment
(RR~3.5) and an increased UPDRS instability score (RR~2). Interestingly, rigidity and
tremor at baseline visit did not noticeably influence either future loss of ability to work or
future loss of ability to live independently.
One previous study found that most patients report loss of independence on ≥2 ADL/IADL
domains when their UPDRS score reaches >60 at best functioning, approximately 7 years
after PD diagnosis [9]. Another study identified axial impairment as strongly associated with
disability assessed with three different ADL scales [8]. However, this cross-sectional study
was conducted exclusively in patients with mild to moderate PD. Comparably, the
systematic review by Post et al. found strong evidence for axial impairment being a
predictor for progression of disability [7], and a study by Shulman et al [9] found that
needing help with walking preceded problems with housework, dressing, transferring in and
out of bed, and traveling in the community. These data are in line with our results showing
that Hoehn and Yahr stage >2 and higher instability score are strongly associated with an
increased risk for loss of ability to live independently.
In our cohort from the US, the estimated proportion of patients still able to work 5 years
after baseline visit ranged from 88% (age ≤70, disease duration ≤4 years) to 43% (age >70,
disease duration >4 years). After 10 years, these figures reached 44% and 3%, respectively.
These results are considerably higher than those of previous surveys in the UK and Finland,
which could reflect cultural and social differences [1, 6]. The patients in this study may also
have benefited from care provided by a movement disorders specialist. However, despite
methodological differences with our study, the survival analysis by Schrag et al. revealed
that 54% of patients with disease onset <65 years still worked after 5 years from disease
onset, and that >80 % of patients with PD with disease onset <65 years lost their
employment within 10 years of disease onset [5]. Additionally, previous studies on quality
of life in PD reported that about 25% of patients prematurely retired or were unemployed
because of PD [2, 4]. In the study by Banks et al. it was reported that the mean age of
premature retirement due to PD was 50.1 years in the UK [6].
Our study has several limitations. The length of time to loss of ability to work and loss of
ability to live independently was likely overestimated. That is, time of clinical assessment
was used as the event date, although the event may have occurred prior to the follow-up
visit. Also, we excluded 330 patients due to a lack of follow-up or insufficient data, which
raises the possibility that our results may be biased. Excluded patients may have had slightly
more advanced disease than the 495 patients included in this study based on our
comparisons of the two groups, which could result in our Kaplan-Meier estimates being
biased too high. However, this would not affect the results of the association analysis
presented in Table 2. Finally, we acknowledge that this is a clinic-based cohort. However,
our previous reports would suggest that both demographic and clinical features are similar to
population-based series [13].
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Despite the above limitations, the present study includes prospective data collected from a
large cohort of patients with an extended follow-up period and at least one follow-up visit,
as opposed to the retrospective and cross-sectional nature of other studies from literature.
Additionally, we analyzed a wide range of demographic, historical and clinical features as
potential predictors for future loss of ability to work or live independently. We identified a
number of associations that were significant after correcting for the number of statistical
tests performed, and also provide concrete data that can be used to inform patients about
their likelihood of future loss of ability to work and loss of ability to live independently
based on their current age and disease duration.
PD has a significant economic impact on patients, families and society [14, 19]. The most
recent study on the cost of PD in the US estimated the total annual cost of the disease to be
$23 billion in 2002. As calculated per diagnosed individual per year, the total direct cost of
PD was established at $23,101 and the indirect cost at $25,326 [20, 21]. The loss of income
due to the premature discontinuing of work is one of the largest primary components of
indirect costs associated with PD and moreover, the loss of personal productivity accounts
for almost 50% of the total financial burden [20].
Movement disorders specialists acknowledge that making an effort to prevent disability and
premature termination of employment is needed [22-24]. We also believe that the data
presented here may prevent unnecessary nihilism concerning expectations for work and
independently living, as many patients were able to maintain both of these abilities.
Examining the associations of patient characteristics and disease information with ability to
work, estimating time to loss of ability to work as well as identifying its predictors may help
reducing both the risk and the impact of future unemployment. Similarly, time before overt
clinical disability and dependent living may provide a window for therapeutic interventions
preventing or delaying the occurrence of disability.
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Figure 1.
A. Kaplan-Meier estimated proportion of patients still able to work after baseline visit,
stratified by age at baseline visit and disease duration (DD)
B. Kaplan-Meier estimated proportion of patients still able to live independently after
baseline visit, stratified by age at baseline visit and disease duration (DD)
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Table 1
Patient demographic and disease information at baseline visit
Variable Summary (N=495)
Age at first visit (years) 71 (38, 93)
Gender (Male) 338 (68%)
Age at PD onset 66 (16, 90)
Disease duration (months) 45 (2, 621)
Personal history of depression 154 (31%)
Current depression 60 (12%)
Family history of movement disorders 136 (27%)
Family history of PD 76 (15%)
Intellectual impairment 29 (6%)
Hoehn and Yahr stage (>2) 131 (27%)
ADL score (any impairment) 83 (17%)
UPDRS – tremor 2 (0, 18)
UPDRS – rigidity 7 (0, 16)
UPDRS – bradykinesia 14 (0, 39)
UPDRS – instability 2 (0, 11)
UPDRS – dyskinesia (>0) 76 (16%)
UPDRS – total 25 (0, 64)
• The sample median (minimum, maximum) is given for numerical variables. Information was unavailable regarding intellectual impairment
(N=16), Hoehn and Yahr stage (N=16), UPDRS – tremor (N=16), UPDRS – rigidity (N=16), UPDRS – bradykinesia (N=16), UPDRS – instability
(N=16), UPDRS – dyskinesia (N=16), UPDRS – total (N=16), and UPDRS – dominance score (N=16). PD, Parkinson’s disease; UPDRS, Unified
Parkinson’s Disease Rating Scale.
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Table 2
Kaplan-Meier estimated proportion of patients still able to work and still able to live independently after
baseline visit, stratified by age at baseline and disease duration
Proportion of patients still able to work or live independently (95% CI)
Time after
baseline visit
Age ≤70, Disease
duration ≤4 years
Age ≤70, Disease
duration >4 years
Age >70, Disease
duration ≤4 years
Age >70, Disease
duration >4 years
Ability to work N=108 N=60 N=85 N=50
 1 year 99% (97% - 100%) 95% (89% - 100%) 95% (91% - 100%) 89% (80% - 99%)
 2 years 97% (94% - 100%) 88% (79% - 97%) 90% (83% - 97%) 79% (68% - 92%)
 3 years 94% (89% - 99%) 82% (73% - 93%) 77% (68% - 87%) 61% (48% - 78%)
 4 years 91% (86% - 97%) 72% (61% - 85%) 70% (60% - 81%) 56% (42% - 74%)
 5 years 88% (81% - 95%) 66% (55% - 80%) 58% (47% - 71%) 43% (30% - 63%)
 6 years 82% (74% - 91%) 58% (46% - 73%) 52% (41% - 66%) 27% (16% - 48%)
 8 years 64% (52% - 77%) 38% (26% - 55%) 35% (24% - 50%) 14% (6% - 33%)
 10 years 44% (28% - 59%) 26% (15% - 44%) 8% (3% - 23%) 3% (1% - 23%)
Ability to live
independently
N=129 N=111 N=129 N=122
 1 year 100% (97% - 100%) 97% (94% - 100%) 98% (95% - 100%) 92% (87% - 97%)
 2 years 98% (96% - 100%) 91% (85% - 97%) 95% (91% - 99%) 85% (79% - 93%)
 3 years 95% (91% - 99%) 88% (82% - 95%) 90% (85% - 96%) 78% (70% - 87%)
 4 years 92% (87% - 98%) 78% (69% - 87%) 88% (81% - 95%) 67% (57% - 78%)
 5 years 90% (84% - 96%) 68% (58% - 79%) 80% (72% - 90%) 57% (47% - 70%)
 6 years 87% (80% - 94%) 65% (55% - 76%) 76% (67% - 87%) 41% (30% - 56%)
 8 years 83% (75% - 92%) 49% (38% - 64%) 58% (45% - 74%) 27% (17% - 43%)
 10 years 64% (50% - 83%) 31% (20% - 49%) 23% (12% - 46%) 5% (1% - 20%)
• The patient cohort consisted of 495 patients either able to work at baseline or able to live independently at baseline. Kaplan-Meier estimates for
loss of ability to work were evaluated for the 303 patients who were able to work at baseline. Kaplan-Meier estimates for loss of ability to live
independently at baseline were evaluated for the 491 patients who were able to live independently at baseline. Patients were stratified into four
different age and disease duration groups based on the median value of each measure, in order to provide meaningful Kaplan-Meier estimates for
specific patient groups.
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